Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides

Bibliography

• BRAUN J, BOLLOW M, REMLINGER G et al.: Prevalence of spondylarthropathies in HLA B27-positive and -negative blood donors. Arthritic Rheum. (1998) 41:58–67.
   PubMed Web of Science ®Google Scholar
• BRANDT J, BOLLOW M, HABERLE J et al.: Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) (1999) 38:831–836.
   PubMed Web of Science ®Google Scholar
• GRAN JT, HUSBY G, HORDVIK M: Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann. Rheum. Dis. (1985) 44:359–367.
   PubMed Web of Science ®Google Scholar
• SARAUX A, GUEDES C, ALLAIN J et akPrevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. Rheumatol. (1999) 26:2622–2627.
   PubMed Web of Science ®Google Scholar
• SIEPER J, BRAUN J, RUDWALEIT M, BOONEN A, ZINK A: Ankylosing spondylitis: an overview. Ann. Rheum. Dis. (2002) 61\(Suppl. 3):1118-III18.
   Google Scholar
• LAUTERMANN D, BRAUN J: Ankylosing spondylitis — cardiac manifestations. Clin. Exp. Rheumatol. (2002) 20(6, Suppl. 28):S11–515.
   Google Scholar
• BRAUN J, PINCUS T: Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin. Exp. Rheumatol. (2002) 20(6, Suppl. 28):516–522.
   Google Scholar
• WARD MM: Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. (1999) 12(0247–255.
   PubMed Web of Science ®Google Scholar
• VAN TUBERGEN A, COENEN J, LANDEWF R et al: Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. (2002) 47(1):8–16.
   PubMed Web of Science ®Google Scholar
• ZINK A, BRAUN J, LISTING J, WOLLENHAUPT J: Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. German Collaborative Arthritis Centers. Rheumatol (2000) 27:613–622.
   Google Scholar
• ZINK A, LISTING J, KLINDWORTH C, ZEIDLER H: The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann. Rheum. Dis. (2001) 60(3):199–206.
   PubMed Web of Science ®Google Scholar
• BOONEN A, CHORUS A, MIEDEMA H, VAN DER HEIJDE D, VAN DER TEMPEL H, VAN DER LINDEN S: Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann. Rheum. Dis. (2001) 60:353–358.
   PubMed Web of Science ®Google Scholar
• CHORUS AM, BOONEN A, MIEDEMA HS, VAN DER LINDEN S: Employment perspectives of patients with ankylosing spondylitis. Ann. Rheum. Dis. (2002) 61(8):693–699.
   PubMed Web of Science ®Google Scholar
• BOONEN A, VAN DER HEIJDE D, LANDEWE R et al.: Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann. Rheum. Dis. (2002) 61(5):429–437.
   Google Scholar
• LEIRISALO-REPO M: Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum. Dis. North Am. (1998) 24(4):737–751.
   PubMed Web of Science ®Google Scholar
• MAKSYMOWYCH WP, BREBAN M, BRAUN J: Ankylosing spondylitis and current disease-controlling agents: do they work? Best Pract. Res. Clin. Rheumatol (2002) 16(4):619–630.
   PubMed Web of Science ®Google Scholar
• AMOR B, DOUGADOS M, KHAN MA: Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum. Dis. North Am. (1995) 21(1):117–128.
   PubMed Web of Science ®Google Scholar
• VAN TUBERGEN A, LANDEWEE R, VAN DER HEIJDE D et al.: Combined Spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum. (2001) 45(5):430–438.
   Google Scholar
• WARD MM: Predictors of the progression of functional disability in patients with ankylosing spondylitis. ./. Rheumatol (2002) 29(7):1420–1425.
   PubMed Web of Science ®Google Scholar
• BOONEN A, SEVERENS JL: Ankylosing spondylitis: what is the cost to socie, and can it be reduced? Best Pract. Res Clin. Rheumatol (2002) 16(4):691–705.
   PubMed Web of Science ®Google Scholar
• BOONEN A: Socioeconomic consequences of ankylosing spondylitis. Gin. Exp. Rheumatol (2002) 20(6, Suppl. 28):S23–S26.
   Google Scholar
• BRAUN J, VAN DER HEIJDE D, PINCUS T: Novel anti-rheumatic therapies challenge old views on ankylosing spondylitis and other spondyloarthritides. Gin. Exp. Rheumatol (2002) 20(6, Suppl. 28):S1–S2.
   Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Repeated therapy with monoclonal antibody to tumour necrosis factor a (cA2) in patients with rheumatoid arthritis. Lancet (1994) 344(8930):1125–1127.
   PubMed Web of Science ®Google Scholar
• BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl. I Med. (2003) 348:601–608.
   PubMed Web of Science ®Google Scholar
• MCGONAGLE D, GIBBON W, O'CONNOR P, GREEN M, PEASE C, EMERY P: Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum. (1998) 41:694–700.
   PubMed Web of Science ®Google Scholar
• BRAUN J, KHAN MA, SIEPER J: Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Ann. Rheum. Dis. (2000) 59(12):985–994.
   PubMed Web of Science ®Google Scholar
• BRAUN J, SIEPERJ: The sacroiliac joint in the spondyloarthropathies. Curt: Opin. Rheumatol (1996) 8(4):275–287.
   PubMedGoogle Scholar
• BRAUN J, BOLLOW M, EGGENS U, KONIG H, DISTLER A, SIEPERJ: Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritic Rheum. (1994) 37:1039–1045.
   PubMed Web of Science ®Google Scholar
• MUCHE B, BOLLOW M, FRANCOIS RJ, SIEPERJ, HAMM B, BRAUN J: Which anatomical structures are involved in early and late sacroiliitis in spondyloarthritis - a detailed analysis by contrast enhanced magnetic resonance imaging. Arthritis Rheum. (2003) (In press).
   Google Scholar
• BRAUN J, BOLLOW M, NEURE L et al: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. (1995) 38:499–505.
   PubMed Web of Science ®Google Scholar
• LALOUX L, VOISIN MC, ALLAIN J et al.: Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. (2001) 60:316–321.
   PubMed Web of Science ®Google Scholar
• BOLLOW M, FISCHER T, REI13HAUER H, SIEPER J, HAMM B, BRAUN J: T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies. Ann. Rheum. Dis. (2000) 59(2):135–140.
   PubMed Web of Science ®Google Scholar
• MIELANTS H, VEYS EM: HLA B27-related arthritis and bowel inflammation: Sulfasalazine in HLA B27-related arthritis. Rheumatol (1985) 12:287–293.
   Web of Science ®Google Scholar
• SANDBORN WJ: Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm. Bowel Dis. (1999) 5:119–133.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 359:1541–1548.
   PubMed Web of Science ®Google Scholar
• SANDS BE, TREMAINE WJ, SANDBORN WJ et al.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis. (2001) 7(2):83–88.
   PubMed Web of Science ®Google Scholar
• LICHTENSTEIN GR: Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm. Bowel Dis. (2001) 7(2):89–93.
   PubMed Web of Science ®Google Scholar
• SU C, SALZBERG BA, LEWIS JD et al:Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am. Gastroenterol (2002) 97(10):2577–2584.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER SB, KATZ S et al: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121(5):1088–1094.
   PubMed Web of Science ®Google Scholar
• MARZO-ORTEGA H, MCGONAGLE D, O'CONNOR P, EMERY P: Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann. Rheum. Dis. (2003) 62(1):74–76.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, LEMMENS L, VAN ASSCHE G, NOMAN M, BORGHINI-FUHRER I, GOEDKOOP R: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open- label, pilot study. Aliment. Phannacol Thar. (2003) 17(2):185–192.
   PubMed Web of Science ®Google Scholar
• VAN DEN BOSCH F, KRUITHOF E, DE VOS M, DE KEYSER F, MIELANTS H: Crohn's disease associated with spondyloarthropathy: effect of TNF-a blockade with infliximab on articular symptoms. Lancet (2000) 356(9244):1821–1822.
   PubMed Web of Science ®Google Scholar
• CHAUDHARI U, ROMANO P, MULCAHY LD, DOOLEY LT, BAKER DG, GOTTLIEB AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 357(9271):1842–1847.
   PubMed Web of Science ®Google Scholar
• OGILVIE AL, ANTONI C, DECHANT C et al: Treatment of psoriatic arthritis with antitumour necrosis factor-a antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br. Dermatol (2001) 144:587–589.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 29(356):385–390.
   Web of Science ®Google Scholar
• ANTONI C, DECHANT C, HANNS-MARTIN LORENZ PD et al.: Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. (2002) 47(5):506–512.
   Google Scholar
• MEASE P: Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann. Rheum. Dis. (2002) 61(4):298–304.
   PubMed Web of Science ®Google Scholar
• BRAUN J, SIEPER J: Role of novel biologic therapies in psoriatic arthritis - effects on joints and skin. BioDrugs (2003) 17(3):187–199.
   PubMed Web of Science ®Google Scholar
• BRANDT J, HAIBEL H, CORNELY D et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor a monoclonal antibody infliximab. Arthritis Rheum. (2000) 43:1346–1352.
   PubMed Web of Science ®Google Scholar
• GARRETT S, JENKINSON TR, KENNEDY LG, WHITELOCK HC, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis. The Bath AS disease activity index. J. Rheumatol. (1994) 21:2286–2291.
   Google Scholar
• BRANDT J, HAIBEL H, REDDIG J, SIEPER J, BRAUN J: Treatment of patients with severe ankylosing spondylitis with infliximab - a one year follow up. Arthritic Rheum. (2001) 44(12):2936–2937.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab - a double-blind placebo controlled multicenter trial. Lancet (2002) 359:1187–1193.
   Google Scholar
• VAN DEN BOSCH F, KRUITHOF E, BAETEN D, DE KEYSER F, MIELANTS H, VEYS EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor a (infliximab) in spondyloarthropathy: an open pilot study. Ann. Rheum. Dis. (2000) 59:428–433.
   PubMed Web of Science ®Google Scholar
• KRUITHOF E, VAN DEN BOSCH F, BAETEN D et al.: Repeated infusions of infliximab, a chimeric anti-TNFa monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann. Rheum. Dis. (2002) 61:207–212.
   Google Scholar
• STONE M, SALONEN D, LAX M, PAYNE U, LAPP V, INMAN R: Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. Rheumatol. (2001) 28(7):1605–1614.
   Web of Science ®Google Scholar
• MAKSYMOWYCH WP, JHANGRI GS, LAMBERT RG et al: Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety../. Rheumatol. (2002) 29:959–965.
   PubMed Web of Science ®Google Scholar
• BREBAN M, VIGNON E, CLAUDEPIERRE P et al: Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) (2002) 41(11):1280–1285.
   PubMed Web of Science ®Google Scholar
• COLLANTES E, MUNOZ- VILLANUEVA MC, SANMARTI R et al: Infliximab in refractory Spondyloarthropathies, preliminary results in a Spanish population. Ann. Rheum. Dis. (2003) (In press).
   Google Scholar
• BRANDT J, SIEPER J, BRAUN J: Infliximab in the treatment of active and severe ankylosing spondylitis. Clin. Exp. Rheumatol. (2002) 20(6, Suppl. 28):5106–S110.
   Google Scholar
• BRAUN J, BREBAN M, MAKSYMOWYCH WP: Therapy for ankylosing spondylitis: new treatment modalities. Best Pract. Res. Clin. Rheumatol. (2002) 16(4):631–651.
   PubMed Web of Science ®Google Scholar
• ALLALI F, ROUX C, KOLTA S et al: Infliximab in the treatment of spondylarthropathy, bone mineral density effect. Arthritis Rheum. (2001) 44(9):S89.
   Web of Science ®Google Scholar
• VAN DEN BOSCH F, KRUITHOF E, BAETEN D et al: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (infliximab) versus placebo in active spondyloarthropathy. Arthritic Rheum. (2002) 46:755–765.
   PubMed Web of Science ®Google Scholar
• D'AGOSTINO MA, BREBAN M, SAID-NAHAL R, DOUGADOS M: Refractory inflammatory heel pain in spondyloarthropathy: a significant response to infliximab documented by ultrasound. Arthritis Rheum. (2002) 46:840–841.
   PubMed Web of Science ®Google Scholar
• D'AGOSTINO MA, SAID-NAHAL R, HACQUARD-BOUDER C, BRASSEUR JL, DOUGADOS M, BREBAN M: Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: A cross-sectional study. Arthritis Rheum. (2003) 48 (2) : 523–533.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BARALIAKOS X, GOLDER W et al: MRI examinations of the spine in patients with ankylosing spondylitis (AS) before and after infliximab therapy after evaluation of a new scoring system. Arthritic Rheum. (2003) 48(4):1126–1136. H.- BRAUN J, SIEPER J: Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-a therapy and other novel approaches. Arthritis Res. (2002) 4(5):307–321.
   Google Scholar
• BRANDT J, HAIBEL H, REDDIG J, SIEPER J, BRAUN J: Successful treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor a monoclonal antibody infliximab. Rheumatol. (2002) 29:118–122.
   Web of Science ®Google Scholar
• MARZO-ORTEGA H, MCGONAGLE D, O'CONNOR P, EMERY P: Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritic Rheum. (2001) 44(9):2112–2117.
   PubMed Web of Science ®Google Scholar
• GORMAN JD, SACK KE, DAVIS JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N. Engl. J. Med. (2002) 346(18):1349–1356.
   PubMed Web of Science ®Google Scholar
• BRANDT J, KARIOUZOV A, LISTING J et al.: Six months results of a German double-blind placebo controlled clinical 1107 trial of etanercept in active ankylosing spondylitis. Arthritic Rheum. (2003) 48(6):1667–1675.
   PubMed Web of Science ®Google Scholar
• CLEGG DO, REDA DJ, MEJIAS E et al:Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritic Rheum. (1996) 39:2013–2020.
   PubMed Web of Science ®Google Scholar
• KIRBY B, MARSLAND AM, CARMICHAEL AJ, GRIFFITHS CE: Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin. Exp. Dermatol (2001) 26(1):27–29.
   PubMed Web of Science ®Google Scholar
• WOLLINA U, KONRAD H: Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-a antibody. J. Ear: Acad. Dermatol Venereol (2002) 16(2):127–129.
   PubMed Web of Science ®Google Scholar
• MEADOR R, HSIA E, KITUMNUAYPONG T, SCHUMACHER HR: TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clin. Exp. Rheumatol (2002) 20(6, Suppl. 28):S130–S134.
   Google Scholar
• DOUGADOS M, VAN DER LINDEN S, JUHLIN R et al.: The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritic Rheum. (1991) 34(10):1218–1227.
   Google Scholar
• BRANDT J, BOLLOW M, HABERLE J et al.: Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) (1999) 38(9):831–836.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BOLLOW M, SIEPER J: Radiology and pathology of the spondyloarthropathies. Rheum. Dis. Clio. N Am. (1998) 24:697–735.
   PubMed Web of Science ®Google Scholar
• BRAUN J, GOLDER W, BOLLOW M, SIEPERJ, VAN DER HEIJDE D: Imaging and scoring in ankylosing spondylitis. Clio. Exp. Rheumatol (2002) 20(6, Suppl. 28):5178–5184.
   Google Scholar
• MAU W, ZEIDLER H, MAU R et al: Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year follow up. Rheumatol (1988) 15(7):1109–1114.
   Google Scholar
• SAMPAIO-BARROS PD, BERTOLO MB, KRAEMER MH, MARQUES-NETO JF, SAMARA AM: Undifferentiated spondyloarthropathies: a 2-year follow-up study. Clio. Rheumatol (2001) 20(3):201–206.
   PubMed Web of Science ®Google Scholar
• DOUBREMELLE M, BOURREILLE A, ZERBIB F et al.: Treatment of Crohn's disease with anti-TNF a antibodies (infliximab): results of a multicentric and retrospective study. Castroenterol Clio. Biol. (2002) 26(11):973–979.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, VAM DER LINDEN S, LEIRISALO-REPO M et al.: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. (1995) 38(5):618–627.
   Google Scholar
• BENITEZ-DEL-CASTILLO JM, GARCIA-SANCHEZ J, IRADIER T, BANARES A: Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (2000) 14:340–343.
   PubMed Web of Science ®Google Scholar
• SMITH JR, LEVINSON RD, HOLLAND GN et al.: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. (2001) 45(3):252–257.
   PubMed Web of Science ®Google Scholar
• REIFF A, TAKEI S, SADEGHI S et al.: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. (2001) 44(6):1411–1415.
   PubMed Web of Science ®Google Scholar
• EL-SHABRAWI Y, HERMANN J: Anti-tumor necrosis factor-a therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology (2002) 109(12):2342–2346.
   PubMed Web of Science ®Google Scholar
• KRUITHOF E, KESTELYN P, ELEWAUT C et al.: Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann. Rheum. Dis. (2002) 61(5):470.
   PubMed Web of Science ®Google Scholar
• FRIES W, GIOFRE MR, CATANOSO M, LO GR: Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am..). Castroenterol (2002) 97(2):499–500.
   PubMed Web of Science ®Google Scholar
• BRAUN J, SIEPER J: Arthritis Rheum. (2002) 46:2822-2824 (Letter).
   Google Scholar
• BRAUN J, SIEPER J, BREBAN M et al.: Anti-tumour necrosis factor a therapy for ankylosing spondylitis: international experience. Ann. Rheum. Dis. (2002) 61 (Suppl. 3):11151–11160.
   Google Scholar
• SIEPER J, BRAUN J: New treatment strategies in ankylosing spondylitis: Proceedings of the Ankylosing Spondylitis Workshop, Berlin, Germany, 18–19 January 2002. Ann. Rheum. Dis. (2002) 61 (Suppl. 3):1111–1112.
   Google Scholar
• BRAUN J, SIEPER J: Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18–19 January 2002. Ann. Rheum. Dis. (2002) 61 (Suppl. 3) :11161–11167.
   Google Scholar
• BRAUN J, SIEPER J: Anti-TNF therapy and the spondyloarthritides: who should be treated? Clio. Exp. Rheumatol (2002) 20(6, Suppl. 28):5187.
   Google Scholar
• ANTONI C, BRAUN J: Side effects of anti-TNF therapy: current knowledge. Clio. Exp. Rheumatol (2002) 20(6, Suppl. 28):5152–5157.
   Google Scholar
• KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl. J. Med. (2001) 345(15):1098–1104.
   PubMed Web of Science ®Google Scholar
• ROBINSON WH, GENOVESE MC, MORELAND LW: Demyelinating and neurologic events reported in association with tumor necrosis factor a antagonism: by what mechanisms could tumor necrosis factor a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum. (2001) 44(9):1977–1983.
   Google Scholar
• BROWN SL, GREENE MH, GERSHON SK, EDWARDS ET, BRAUN MM: Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. (2002) 46(12):3151–3158.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-BORRA J, LOPEZ-LARREA C, GONZALEZ S et al.: High serum tumor necrosis factor-a levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am. J. Castroenterol (2002) 97(9):2350–2356.
   PubMed Web of Science ®Google Scholar
• YIN Z, BRAUN J, NEURE Let al.: Crucial role of interleukin-10/interleukin-12 balance in the regulation of the Type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum. (1997) 40:1788–1799.
   Google Scholar
• BRAUN J, YIN Z, SPILLER let al.: Low secretion of tumor necrosis factor a, but no other Thl or Th2 cytokines, by peripheral blood mononuclear cells correlates with 1108 Expert Op/n. Investig. Drugs (2003) 12(7) chronicity in reactive arthritis. Arthritis Rheum. (1999) 42(10):2039–2044.
   Google Scholar
• CANETE JD, MARTINEZ SE, FARRES J et al.: Differential Thl/Th2 cytokine patterns in chronic arthritis: interferon-y is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann. Rheum. Dis. (2000) 59:263–268.
   PubMed Web of Science ®Google Scholar
• RUDWALEIT M, ANDERMANN B, ALTEN R et al.: Atopic disorders in ankylosing spondylitis and rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61(11):968–974.
   PubMed Web of Science ®Google Scholar
• RUDWALEIT M, SIEGERT S, YIN Z et al.: Low T cell production of TNF-a and IFNI/ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 Gene Polymorphism. Ann. Rheum. Dis. (2001) 60:36–42.
   PubMed Web of Science ®Google Scholar
• BAETEN D, VAN DAMME N, VAN DEN BOSCH F et al.: Impaired Thl cytokine production in spondyloarthropathy is restored by anti-TNF-a. Ann. Rheum. Dis. (2001) 60(8):750–755.
   Google Scholar
• BRAUN J, XIANG J, BRANDT J et al: Treatment of spondyloarthropathies with antibodies against tumour necrosis factor a: first clinical and laboratory experiences. Ann. Rheum. Dis. (2000) 59(Suppl. I):10–14.
   Google Scholar
• XIANG J, RUDWALEIT M, THIEL A, BRAUN J, SIEPER J: Downregulation of the nonspecific and the antigen-specific T cell cytokine response in ankylosing spondylitis after treatment with infliximab. Arthritis Rheum. (2001) 44:S236.
   Google Scholar
• XIANG J, RUDWALEIT M, THIEL A et al.: Cellular immune response to the cartilage-derived autoantigen G1 of aggrecan in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. (2001) 44:S236.
   Google Scholar
• LEROUX JY, GUERASSIMOV A et al.: Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratansulfate in vitro and in vivo. j. Clin. Invest. (1996) 97:621–632.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, GUERASSIMOV A, LEROUX JY et al.: Arthritis induced by proteoglycan aggrecan G1 domain in BALB/c mice. Evidence for T cell involvement and the immunosuppressive influence of keratan sulfate on recognition of T and B cell epitopes. j Clin. Invest. (1998) 101:1678-1686. llo. ZOU JX, BRAUN J, SIEPER J: Immunological basis for the use of TNFa-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin. Exp. Rheumatol. (2002) 20(6, Suppl. 28):534–537.
   Google Scholar
• BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al.: Immunomodulatory effects of anti-tumor necrosis factor a therapy on synovium in spondylarthropathy. Histologic findings in eight patients from an open-label pilot study. Arthritis Rheum. (2001) 44:186–195.
   Google Scholar
• MASCHERETTI S, HAMPE J, KUHBACHER T et al.: Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J. (2002) 2(2):127–136.
   PubMedGoogle Scholar
• VAN DER HEIJDE D, BRAUN J, MCGONAGLE D, SIEGEL J: Treatment trials in ankylosing spondylitis: current and future considerations. Ann. Rheum. Dis. (2002) 61 (Suppl. 3) :11124–11132.
   Google Scholar
• VAN DER HEIJDE D, BELLAMY N, CALIN A, DOUGADOS M, KHAN MA, VAN DER LINDEN S: Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J. Rheumatol. (1997) 24:2225–2229.
   Google Scholar
• ANDERSON JJ, BARON G, VAN DER HEIJDE D, FELSON DT, FELSON M: ASAS preliminary criteria for short term improvement in ankylosing spondylitis. Arthritis Rheum. (2001) 44:1878–1886.
   Web of Science ®Google Scholar
• VAN TUBERGEN A, VAN DER HEIJDE D, ANDERSON Jet al.: Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann. Rheum. Dis. (2003) 62(3):215–221.
   Google Scholar
• GARRETT S, JENKINSON TR, KENNEDY LG, WHITELOCK HC, GAISFORD P, CALIN A:A new approach to defining disease status in ankylosing spondylitis. The Bath AS disease activity index. J. Rheumatol. (1994) 21:2286–2291.
   Google Scholar
• BRANDT J, LISTING J, SIEPER J, VAN DER HEIJDE D, BRAUN J: Improvement criteria for treatment with biologics of patients with ankylosing spondylitis - a proposal based on data from a recent randomized trial with the anti-TNFa agent infliximab. Arthritis Rheum. (2002) 46:S380.
   Web of Science ®Google Scholar
• BRAUN J, PHAM T, SIEPER J et al: International ASAS consensus statement for the use of biologic agents in patients with ankylosing spondylitis. Ann. Rheum. Dis. (2003) (In press).
   Google Scholar
• BRAUN J, VAN DER HEIJDE D, DOUGADOS M et al.: Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann. Rheum. Dis. (2002) 61\(Suppl. 3) :11119–11123.
   Google Scholar
• SPOORENBERG A, DE VLAM K, VAN DER HEIJDE D et al.: Radiologic scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J. Rheumatol. (1999) 26:997–1002.
   Google Scholar
• MACKAY K, MACK C, BROPHY S, CALIN A: The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum. (1998) 41:2263–2270.
   PubMed Web of Science ®Google Scholar
• AVERNS HL, OXTOBY J, TAYLOR HG, JONES PW, DZIEDZIC K, DAWES PT: Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br. Rheumatol. (1996) 35:373–376.
   PubMedGoogle Scholar
• BOLLOW M, ENZWEILER C, TAUPITZ M et al.: Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides. Clin. Exp. Rheumatol. (2002) 20(6, Suppl. 28):5167–5174.
   Google Scholar
• BRAUN J, VAN DER HEIJDE D: Imaging and scoring in ankylosing spondylitis. Best Pract. Res. Clin. Rheumatol. (2002) 16(4):573–604.
   PubMed Web of Science ®Google Scholar
• AMOR B, SANTOS RS, NAHAL R, LISTRAT V, DOUGADOS M: Predictive factors for the longterm outcome of spondyloarthropathies. Rheumatol. (1994) 21(10):1883–1887.
   Web of Science ®Google Scholar